Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALHC Alignment Healthcare	$14.92 -1.3%	$17.33	$6.66 ▼ $21.06	$2.95B	1.32	1.83 million shs	2.08 million shs
LMAT LeMaitre Vascular	$82.46 +2.7%	$84.15	$71.42 ▼ $109.58	$1.86B	0.86	163,418 shs	195,917 shs
NXGN NextGen Healthcare	$23.94	$23.89	$15.23 ▼ $23.98	$1.61B	0.77	659,586 shs	N/A
REPL Replimune Group	$7.86 +1.9%	$9.36	$4.92 ▼ $17.00	$605.34M	0.68	898,815 shs	764,794 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALHC Alignment Healthcare	0.00%	-2.64%	-23.40%	+4.78%	+121.38%
LMAT LeMaitre Vascular	0.00%	+1.91%	-3.16%	-18.53%	+5.35%
NXGN NextGen Healthcare	0.00%	0.00%	0.00%	0.00%	0.00%
REPL Replimune Group	0.00%	-22.98%	+4.90%	-41.23%	+20.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALHC Alignment Healthcare	2.7992 of 5 stars	3.3	2.0	0.0	0.0	4.1	2.5	0.6
LMAT LeMaitre Vascular	2.9797 of 5 stars	2.3	1.0	3.3	0.0	3.4	3.3	1.3
NXGN NextGen Healthcare	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	4.2809 of 5 stars	3.6	2.0	0.0	4.5	3.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALHC Alignment Healthcare	2.67	Moderate Buy	$17.17	15.06% Upside
LMAT LeMaitre Vascular	2.63	Moderate Buy	$98.14	19.02% Upside
NXGN NextGen Healthcare	0.00	N/A	N/A	N/A
REPL Replimune Group	3.13	Buy	$19.43	147.18% Upside

Current Analyst Ratings Breakdown

Latest NXGN, LMAT, REPL, and ALHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/2/2025	ALHC Alignment Healthcare	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$16.00 ➝ $17.00
4/15/2025	ALHC Alignment Healthcare	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$17.00 ➝ $22.00
4/8/2025	ALHC Alignment Healthcare	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $23.00
3/6/2025	ALHC Alignment Healthcare	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$14.00 ➝ $17.00
3/4/2025	ALHC Alignment Healthcare	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $21.00
3/4/2025	ALHC Alignment Healthcare	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.50 ➝ $18.50
2/28/2025	ALHC Alignment Healthcare	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $18.00
2/28/2025	ALHC Alignment Healthcare	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/28/2025	ALHC Alignment Healthcare	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$8.00 ➝ $9.00
2/28/2025	LMAT LeMaitre Vascular	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $110.00
2/28/2025	LMAT LeMaitre Vascular	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALHC Alignment Healthcare	$3.00B	0.98	N/A	N/A	$0.84 per share	17.76
LMAT LeMaitre Vascular	$226.26M	8.23	$1.46 per share	56.52	$13.38 per share	6.16
NXGN NextGen Healthcare	$653.17M	2.46	$1.16 per share	20.57	$6.31 per share	3.79
REPL Replimune Group	N/A	N/A	N/A	N/A	$6.26 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALHC Alignment Healthcare	-$148.02M	-$0.48	N/A	N/A	N/A	-5.84%	-108.69%	-21.89%	N/A
LMAT LeMaitre Vascular	$30.10M	$1.98	45.06	38.00	2.22	19.40%	13.15%	11.47%	N/A
NXGN NextGen Healthcare	-$2.65M	-$0.10	N/A	27.52	N/A	-0.89%	11.37%	5.38%	N/A
REPL Replimune Group	-$215.79M	-$3.07	N/A	N/A	N/A	N/A	-54.84%	-42.97%	5/15/2025 (Estimated)

Latest NXGN, LMAT, REPL, and ALHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q4 2025	REPL Replimune Group	-$0.75	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	ALHC Alignment Healthcare	-$0.12	-$0.05	+$0.07	-$0.05	$889.83 million	$926.93 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
2/27/2025	Q4 2024	LMAT LeMaitre Vascular	$0.49	$0.49	N/A	$0.49	$55.99 million	$55.81 million
2/12/2025	Q3 2025	REPL Replimune Group	-$0.70	-$0.79	-$0.09	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALHC Alignment Healthcare	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.97%	+13.30%	40.40%	14 Years
NXGN NextGen Healthcare	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Latest NXGN, LMAT, REPL, and ALHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025
2/18/2025	LMAT LeMaitre Vascular	quarterly	$0.20	0.9%	3/13/2025	3/13/2025	3/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALHC Alignment Healthcare	1.82	1.60	1.60
LMAT LeMaitre Vascular	N/A	7.74	5.52
NXGN NextGen Healthcare	0.63	2.52	2.52
REPL Replimune Group	0.14	11.43	11.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALHC Alignment Healthcare	86.19%
LMAT LeMaitre Vascular	84.64%
NXGN NextGen Healthcare	76.65%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
ALHC Alignment Healthcare	7.00%
LMAT LeMaitre Vascular	10.79%
NXGN NextGen Healthcare	4.60%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALHC Alignment Healthcare	850	197.84 million	179.04 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.06 million	Optionable
NXGN NextGen Healthcare	2,783	67.10 million	64.01 million	Optionable
REPL Replimune Group	210	77.02 million	70.24 million	Optionable

NXGN, LMAT, REPL, and ALHC Headlines

Recent News About These Companies

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Dimensional Fund Advisors LP

May 12 at 3:28 AM | marketbeat.com

Fcpm Iii Services B.V. Has $48.09 Million Position in Replimune Group, Inc. (NASDAQ:REPL)

May 11 at 7:39 AM | marketbeat.com

Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) PT at $19.43

May 11 at 3:09 AM | americanbankingnews.com

172,202 Shares in Replimune Group, Inc. (NASDAQ:REPL) Bought by Crestline Management LP

May 10 at 6:05 AM | marketbeat.com

Replimune Group (REPL) Projected to Post Earnings on Thursday

May 10 at 1:53 AM | marketbeat.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9 at 4:01 PM | globenewswire.com

Braidwell LP Has $17.89 Million Position in Replimune Group, Inc. (NASDAQ:REPL)

May 8, 2025 | marketbeat.com

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025 | globenewswire.com

Replimune Group, Inc. (NASDAQ:REPL) Stock Holdings Cut by Schonfeld Strategic Advisors LLC

May 8, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Analysts

May 8, 2025 | marketbeat.com

Boxer Capital Management LLC Buys Shares of 1,796,341 Replimune Group, Inc. (NASDAQ:REPL)

May 4, 2025 | marketbeat.com

Invesco Ltd. Sells 92,952 Shares of Replimune Group, Inc. (NASDAQ:REPL)

May 4, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Wells Fargo & Company MN

May 2, 2025 | marketbeat.com

Price T Rowe Associates Inc. MD Purchases 1,083,633 Shares of Replimune Group, Inc. (NASDAQ:REPL)

April 29, 2025 | marketbeat.com

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

April 28, 2025 | seekingalpha.com

Renaissance Technologies LLC Buys 49,200 Shares of Replimune Group, Inc. (NASDAQ:REPL)

April 28, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Trading Down 2.9% - Should You Sell?

April 24, 2025 | marketbeat.com

Diadema Partners LP Purchases Shares of 114,000 Replimune Group, Inc. (NASDAQ:REPL)

April 24, 2025 | marketbeat.com

Marshall Wace LLP Takes $10.85 Million Position in Replimune Group, Inc. (NASDAQ:REPL)

April 24, 2025 | marketbeat.com

Jump Financial LLC Has $865,000 Position in Replimune Group, Inc. (NASDAQ:REPL)

April 24, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Up 6.7% - Time to Buy?

April 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXGN, LMAT, REPL, and ALHC Company Descriptions

Alignment Healthcare NASDAQ:ALHC

$14.92 -0.20 (-1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$14.75 -0.17 (-1.17%)

As of 07:03 PM Eastern

Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.

LeMaitre Vascular NASDAQ:LMAT

$82.46 +2.20 (+2.74%)

Closing price 04:00 PM Eastern

Extended Trading

$82.61 +0.15 (+0.18%)

As of 04:20 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NextGen Healthcare NASDAQ:NXGN

NextGen Healthcare, Inc. provides healthcare technology solutions in the United States. The company offers clinical care solutions, including NextGen Enterprise EHR; financial solutions, such as NextGen Enterprise PM; patient engagement solutions comprising NextGen Virtual Visits; integrated clinical care and financial solutions consisting of NextGen Office; interoperability solutions that include NextGen Share and Mirth Connect; data and analytics solutions, which comprise NextGen Health Data Hub; and value based care solutions, including NextGen Population Health Solutions. It also provides managed services, such as revenue cycle management services comprising billing and collections, electronic claims submission and denials management, electronic remittance and payment posting, and accounts receivable follow-up; and client and support services. Further, the company offers professional services consisting of training, project management, installation services, and application managed services; and consulting services that include physician, professional, and technical consulting; assisting clients to optimize their staffing and software solutions; enhancing financial and clinical outcomes; achieving regulatory requirements; and meeting the requirements of healthcare reform. It serves accountable care organizations, independent physician associations, managed service organizations, veterans service organizations, dental service organizations, ambulatory care centers, and community health centers through a direct sales force and reseller channel. The company was formerly known as Quality Systems, Inc. and changed its name to NextGen Healthcare, Inc. in September 2018. NextGen Healthcare, Inc. was incorporated in 1974 and is based in Atlanta, Georgia.

Replimune Group NASDAQ:REPL

$7.86 +0.15 (+1.95%)

Closing price 04:00 PM Eastern

Extended Trading

$8.14 +0.28 (+3.56%)

As of 07:48 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time